Results
|
1.
|
|
|
2.
|
|
|
3.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
|
4.
|
Target organ damage and incident type 2 diabetes mellitus: the Strong Heart Study. MedStar authors:
Year: 2017
Citation: - Cardiovascular Diabetology. 16(1):64, 2017 05 12
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Best LG, de Simone G, Devereux RB, Howard BV, Izzo R, Lee ET, Mancusi C, Roman MJ, Wang W, Yeh F
|
|
5.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|
|
6.
|
Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. MedStar authors:
Year: 2021
Citation: - Cancer. 127(4):598-608, 2021 02 15.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Banack HR, Barac A, Beebe-Dimmer JL, Caan BJ, Chlebowski RT, Foraker R, Hastert TA, Hovsepyan G, Liu S, Luo J, Manson JE, Neuhouser ML, Okwuosa TM, Pan K, Qi L, Ruterbusch JJ, Shadyab AH, Simon MS, Thomson CA, Wactawski-Wende J, Waheed N
|